The stock of Hims & Hers Health, Inc. (NYSE: HIMS) stands at a critical juncture in mid-2025, with technical indicators suggesting a potential breakout or breakdown. Recent price action has drawn attention to a possible ascending wedge formation over the past three weeks, a pattern often indicative of volatility ahead. More importantly, the stock’s fundamentals and market positioning in the telehealth sector provide a robust backdrop to any technical analysis, with a year-to-date gain of nearly 108% as of July 2025. This article delves into the technical setup, validates it with current data, and contextualises the broader performance of HIMS within its industry.
Technical Analysis: Ascending Wedge in Focus
An ascending wedge pattern, typically a bearish reversal signal in an uptrend, appears to be forming on the daily chart for HIMS as of mid-July 2025. This structure is characterised by converging trendlines with higher lows and higher highs, often signalling diminishing momentum despite price increases. Should the stock break above the upper trendline, a bullish surge towards $63 could be on the cards, filling a notable price gap from earlier volatility. Conversely, a failure to hold the lower boundary might see a retracement to around $45, a level that has previously acted as psychological support. This observation aligns with sentiment seen in broader financial discussions, including passing mentions by traders on platforms like X, such as StockTrader_Max, who have noted similar patterns.
Current data supports this technical picture. As of 16 July 2025, HIMS closed at $50.46, reflecting a 3.02% decline for the day, yet it remains significantly above its 52-week low of $13.47. The stock’s 52-week high stands at $72.98, indicating room for upside if momentum shifts favourably. The average price over the last 52 weeks is $32.33, underscoring the dramatic outperformance in 2025 so far.
Fundamental Strength Underpinning Volatility
Beyond the charts, HIMS has demonstrated remarkable growth in 2025, with subscriber increases and heightened demand for its telehealth services driving share price gains. Industry comparisons highlight this strength: while the broader healthcare sector has risen by 13.9% over the past three months (April to June 2025, Q2), HIMS has surged by 90.4% in the same period. This disparity reflects investor confidence in the company’s niche focus on accessible health and wellness solutions, particularly in areas like GLP-1 medications for weight management.
Recent analyst commentary provides further context. Bank of America Securities, in a note dated 18 July 2025, maintained an Underperform rating on HIMS, citing concerns over valuation despite acknowledging strategic marketing efforts around GLP-1 offerings. The firm noted that a significant portion of incremental sales likely stems from compounded GLP-1 drugs, a high-margin area but one subject to regulatory and competitive risks. This caution contrasts with the stock’s market performance, suggesting that technical patterns may be amplified by underlying uncertainty over long-term growth sustainability.
Key Metrics and Ownership Dynamics
To ground the analysis, a snapshot of HIMS’s performance metrics and ownership structure is instructive. The table below summarises critical data as of mid-July 2025:
| Metric | Value (as of 16 July 2025) |
|---|---|
| Closing Price | $50.46 |
| Year-to-Date Gain | 107.8% |
| 52-Week High | $72.98 |
| 52-Week Low | $13.47 |
| 52-Week Average | $32.33 |
Ownership trends also warrant attention. Institutional investors continue to hold significant stakes in HIMS, reflecting confidence despite short-term price swings. Additionally, insider transactions, such as the sale of 2,572 shares by Soleil Boughton on 14 July 2025 at an average price of $47.82, indicate some profit-taking at current levels. While not necessarily a bearish signal, such moves suggest caution among those closest to the company’s operations.
Broader Sector and Macro Context
The telehealth sector remains a bright spot in healthcare, with digital platforms like HIMS benefiting from post-pandemic shifts towards remote care. However, competition is intensifying, and regulatory scrutiny over compounded medications could pose headwinds. Historical data offers perspective: in Q4 2022 (October to December), HIMS reported revenue growth of 88% year-over-year, a figure that moderated to 47% by Q4 2024 as the market matured. While 2025 figures are pending full quarterly disclosure, early indications suggest continued double-digit growth, albeit at a slower pace than the explosive early years.
Macroeconomic factors also play a role. With interest rates remaining elevated in 2025, growth stocks like HIMS face pressure on valuation multiples. Yet, the company’s ability to generate cash flow—evidenced by a $1 billion cash raise in June 2025—provides a buffer against broader market turbulence. This financial stability could be a deciding factor if technical patterns resolve bearishly in the near term.
Conclusion: A Stock at a Crossroads
Hims & Hers Health finds itself at a technical and fundamental inflection point in July 2025. The potential ascending wedge formation hints at a decisive move, with upside targets near $63 or downside risks towards $45. However, the stock’s 108% year-to-date rally and outperformance relative to its sector underscore a business model that continues to resonate with investors. Balancing this optimism are analyst caution and insider sales, which suggest that any breakout must be supported by concrete earnings growth in upcoming quarters. For now, HIMS remains a stock to watch closely, as the interplay of technical signals and fundamental strength will likely dictate its trajectory through the remainder of Q3 2025 (July to September).
References
- Daily Political. (2025, July 17). Soleil Boughton Sells 2,572 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock. Retrieved from https://www.dailypolitical.com/2025/07/17/soleil-boughton-sells-2572-shares-of-hims-hers-health-inc-nysehims-stock.html
- Investing.com. (2025, July 18). BofA Securities maintains Hims and Hers stock rating at Underperform. Retrieved from https://www.investing.com/news/analyst-ratings/bofa-securities-maintains-hims-and-hers-stock-rating-at-underperform-93CH-4141460
- MacroTrends. (2025, June 23). Hims & Hers Health – 6 Year Stock Price History. Retrieved from https://www.macrotrends.net/stocks/charts/HIMS/hims-hers-health/stock-price-history
- Nasdaq. (2025, July 15). Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know. Retrieved from https://nasdaq.com/articles/hims-hers-health-inc-hims-dips-more-broader-market-what-you-should-know
- Simply Wall St. (2025). Hims & Hers Health (NYSE:HIMS) Stock Price, News & Analysis. Retrieved from https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health
- StockAnalysis.com. (2025). Hims & Hers Health, Inc. (HIMS) Stock Price, Quote & News. Retrieved from https://stockanalysis.com/stocks/hims/
- StockTrader_Max. (2025a, July 16). [Post on X]. Retrieved from https://x.com/StockTrader_Max/status/1937522487069221127
- StockTrader_Max. (2025b, July 16). [Post on X]. Retrieved from https://x.com/StockTrader_Max/status/1937923364540342545
- StockTrader_Max. (2025c, July 16). [Post on X]. Retrieved from https://x.com/StockTrader_Max/status/1937438877326745926
- StockTrader_Max. (2025d, July 17). [Post on X]. Retrieved from https://x.com/StockTrader_Max/status/1938271210053288436
- StockTrader_Max. (2025e, July 17). [Post on X]. Retrieved from https://x.com/StockTrader_Max/status/1938594106785095702
- TipRanks.com. (2025, July 16). With Hims & Hers Health Stock (HIMS) Up 108%, Let’s Look at Who Owns It. Retrieved from https://www.tipranks.com/news/with-hims-hers-health-stock-hims-up-108-lets-look-at-who-owns-it
- TradingView. (2025). HIMS Stock Price and Chart — NYSE:HIMS. Retrieved from https://www.tradingview.com/symbols/NYSE-HIMS/
- TradingView News. (2025, July 17). Hims & Hers Stock Surges 90.4% in 3 Months: What’s Fueling the Rally? Retrieved from https://www.tradingview.com/news/zacks:7da67ea73094b:0-hims-hers-stock-surges-90-4-in-3-months-what-s-fueling-the-rally/
- Yahoo Finance. (2025, July 2). Hims & Hers Health, Inc. (HIMS) Stock Price, News, Quote & History. Retrieved from https://finance.yahoo.com/quote/HIMS/
